Clinical resistance to platinum chemotherapy in ovarian cancer
Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results from DNA crosslinking. High tumour response rates are seen, but 80 % of patients relapse. Major mechanisms of platinum resistance in patients remain to be established. We have studied DNA interstrand crosslinking...
Main Author: | Newton, C. |
---|---|
Published: |
University College London (University of London)
2009
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.564599 |
Similar Items
-
Positron emission tomography imaging of platinum resistant ovarian cancer and drug modulation
by: Perumal, Meg
Published: (2012) -
Platinum chemotherapy : investigation of cellular resistance mechanisms and early development of an oral analogue
by: Nicolson, Marianne Coutts
Published: (1996) -
Studies on platinum drugs in ovarian cancer patients
by: Shelley, M. D.
Published: (1987) -
Application of polarised X-ray for the in vivo measurements of platinum in the head and neck and the kidney of cancer patients treated with platinum-based chemotherapy drugs
by: Kadhim, R. A. G.
Published: (2003) -
The use of tomography images in the XRF measurement of platinum in tumours following chemotherapy
by: Ghara'ati, H.
Published: (1994)